Evidence map›Paper›PMID 35717177›Full record

ArticleBMC oral health2022

Complementarity of surgical therapy, photobiomodulation, A-PRF and L-PRF for management of medication-related osteonecrosis of the jaw (MRONJ): an animal study.

Mohammad Reza Jamalpour, Shiva Shahabi, Mehdi Baghestani, Abbas Shokri, Shokoofeh Jamshidi, Salman Khazaei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC oral health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohammad Reza JamalpourDepartment of Oral and Maxillofacial Surgery, Dental Implants Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Shiva ShahabiDental Implants Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. shivashhbi@gmail.com.ORCID 0000-0001-7458-9629
Mehdi BaghestaniDepartment of Oral and Maxillofacial Surgery, Hamadan University of Medical Sciences, Hamadan, Iran.
Abbas ShokriDepartment of Oral and Maxillofacial Radiology, Dental Implants Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Shokoofeh JamshidiDepartment of Oral and Maxillofacial Pathology, Dental Implants Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Salman KhazaeiDepartment of Epidemiology, Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Hamedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the complementarity of surgical therapy, photobiomodulation (PBM), advanced platelet-rich fibrin (A-PRF), and Leukocyte and platelet-rich fibrin (L-PRF) for the management of medication-related osteonecrosis of the jaw (MRONJ).

methodsSixty rats underwent injection of zoledronate followed by left mandibular first and second molar extractions to induce MRONJ lesions. All rats were examined for the signs of MRONJ 8 weeks post-dental extraction. Forty-nine rats with positive signs of MRONJ were appointed to seven different groups as follows: control (Ctrl); surgery alone (Surg); surgery and PBM (Surg + PBM); surgery and A-PRF insertion (Surg + APRF); surgery and L-PRF insertion (Surg + LPRF); surgery, A-PRF insertion, and PBM (Surg + APRF + PBM); surgery, L-PRF insertion, and PBM (Surg + LPRF + PBM). Euthanasia was carried out 30 days after the last treatment session. The lesions' healing was evaluated clinically, histologically, and radiographically. Data were analyzed using STATA software version 14, and the statistical significance level was set at 5% for all cases.

resultsAccording to the present study, A-PRF and L-PRF treatment resulted in significant improvements in clinical, histological, and radiographical parameters compared to the Ctrl group (P < 0.05). The PBM also decreased wound dimensions and the number of empty lacunae compared to the Ctrl group (P < 0.05). Surg + APRF + PBM and Surg + LPRF + PBM were the only groups that presented a significantly higher mean number of osteocytes (P < 0.05). No significant differences were observed between A-PRF and L-PRF treatment groups (P > 0.05).

conclusionsSurgical resection followed by applying A-PRF or L-PRF reinforced by PBM showed optimal wound healing and bone regeneration in MRONJ lesions.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsLow-Level Light TherapyPlatelet-Rich FibrinAnimalsHumansRatsTooth ExtractionZoledronic AcidBone Density Conservation AgentsZoledronic AcidLaser therapyMedication-related osteonecrosis of the jawPhotobiomodulation therapyPlatelet-rich fibrinZoledronate

Identifiers

PMID35717177
PMCPMC9206277
OpenAlexW4283067545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.